Hospital
Adventhealth Polk South INC
Adventhealth Polk South INC was paid $7.13M by Medicaid between Jan 2018 and Dec 2024, across 139 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoADVENTHEALTH POLK SOUTH INC
LAKE WALES, FL 33853
LAKE WALES, FL 33853
33aNPI1033770284assigned 06/27/2019
33bProvider typePsychiatric Hospital Unit
28Total paid$7.13M
24GClaims225,669
24DCodes billed139
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#8 of 15
Median peer was paid$7.13M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,355 | $171K | |
| 2019 | 32,433 | $568K | |
| 2020 | 13,073 | $345K | |
| 2021 | 52,313 | $1.64M | |
| 2022 | 53,022 | $1.80M | |
| 2023 | 43,164 | $1.64M | |
| 2024incomplete | 21,309 | $965K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 21,826 | 20,060 | $2.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 15,275 | 13,571 | $1.28M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.9% | 2,514 | 2,279 | $561K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 5,713 | 4,858 | $465K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.4% | 3,157 | 1,343 | $314K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 3,754 | 3,467 | $303K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,870 | 1,604 | $246K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 6,492 | 5,675 | $205K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 3,418 | 2,978 | $180K |
| G0378 | Hospital observation service, per hour | 2.3% | 1,906 | 883 | $162K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 619 | 579 | $140K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 5,710 | 5,072 | $124K |
127 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 7,397 | $112K |
| 80053 | Comprehensive metabolic panel | 1.4% | 12,488 | $100K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,324 | $84K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 720 | $73K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,362 | $55K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,497 | $48K |
| 82962 | <1% | 988 | $38K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,693 | $36K |
| 97597 | <1% | 395 | $30K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,805 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,736 | $28K |
| 84703 | <1% | 4,086 | $28K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 876 | $28K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,150 | $25K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,050 | $25K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 174 | $24K |
| 87430 | <1% | 960 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,936 | $22K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,706 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,376 | $20K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 26 | $16K |
| 81001 | <1% | 8,575 | $15K | |
| 81003 | <1% | 2,934 | $15K | |
| 82947 | <1% | 1,480 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,328 | $14K |
| 80306 | <1% | 1,717 | $10K | |
| 74018 | <1% | 357 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,493 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 583 | $9K |
| 97161 | <1% | 95 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 48 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,749 | $7K |
| 73562 | <1% | 360 | $6K | |
| 81025 | <1% | 1,157 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,936 | $6K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 328 | $6K |
| 73130 | <1% | 182 | $5K | |
| 73030 | <1% | 111 | $5K | |
| 86756 | <1% | 128 | $4K | |
| 87077 | <1% | 913 | $4K | |
| 73630 | <1% | 291 | $4K | |
| 85730 | <1% | 1,826 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,807 | $4K |
| 84484 | <1% | 5,015 | $4K | |
| 87420 | <1% | 566 | $3K | |
| 87186 | <1% | 812 | $3K | |
| 12001 | <1% | 34 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 49 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,122 | $3K |
| 84702 | <1% | 668 | $3K | |
| 93971 | <1% | 15 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,568 | $3K |
| 83735 | <1% | 1,793 | $2K | |
| 29581 | <1% | 28 | $2K | |
| 87070 | <1% | 2,919 | $2K | |
| 72100 | <1% | 94 | $2K | |
| 74022 | <1% | 114 | $2K | |
| 85610 | <1% | 2,262 | $2K | |
| 73610 | <1% | 180 | $2K | |
| 94760 | <1% | 515 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,701 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 17 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,886 | $1K |
| 01999 | <1% | 624 | $1K | |
| 83690 | <1% | 3,548 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 27 | $1K |
| 80061 | Lipid panel | <1% | 322 | $1K |
| 82077 | <1% | 535 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,097 | $944.28 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,094 | $941.84 |
| 87075 | <1% | 15 | $903.39 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 464 | $902.05 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 32 | $897.68 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 25 | $851.38 |
| 85379 | <1% | 1,009 | $752.65 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 230 | $717.65 |
| 96376 | <1% | 770 | $667.16 | |
| 97116 | <1% | 63 | $559.62 | |
| 83880 | <1% | 730 | $531.72 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $523.22 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,486 | $482.74 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 217 | $443.99 |
| J2704 | Injection, propofol, 10 mg | <1% | 507 | $389.10 |
| 82550 | <1% | 760 | $366.05 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 123 | $264.34 |
| 76801 | <1% | 75 | $260.70 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,785 | $246.36 |
| 72040 | <1% | 17 | $233.84 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 57 | $195.54 |
| 87088 | <1% | 282 | $161.88 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 172 | $114.38 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 41 | $111.36 |
| 85027 | <1% | 234 | $107.51 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 416 | $86.51 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 69 | $83.52 |
| 80305 | <1% | 72 | $81.97 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18 | $42.58 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 307 | $27.49 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 203 | $10.32 |
| 83605 | <1% | 643 | $7.01 | |
| 80050 | General health panel | <1% | 27 | $2.67 |
| 90715 | 0% | 42 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 107 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 41 | $0.00 |
| 73110 | 0% | 12 | $0.00 | |
| 85007 | 0% | 46 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 31 | $0.00 |
| 86900 | 0% | 51 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 29 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 381 | $0.00 |
| 87040 | 0% | 584 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 12 | $0.00 |
| A9270 | Non-covered item or service | 0% | 202 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 550 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 13 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 35 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 109 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 157 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 99 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 27 | $0.00 |
| 86901 | 0% | 51 | $0.00 | |
| 82150 | 0% | 50 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 63 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 69 | $0.00 |
| 82553 | 0% | 14 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENGESBACH, ALAN (CFO)
Parent organizationADVENTHEALTH POLK SOUTH INC
| Provider | Location | Paid |
|---|---|---|
| Adventhealth Polk North INC | Davenport, FL | $15.43M |
| Adventhealth Polk South INC | Lake Wales, FL | $447K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.